Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisavanbulin + Radiation in Newly Diagnosed MGMT Unmethylated Glioblastoma
NCT03250299Phase 1Terminated
- Sponsor
- Basilea Pharmaceutica
- Start
- Dec 2017
- Primary completion
- Jun 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lisavanbulin in glioblastoma (GBM), sponsored by Basilea Pharmaceutica. Primary endpoint: Dose-Limiting Toxicities at 10 weeks. Started Dec 2017; status: terminated.
02
Drugs
lisavanbulin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03250299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250299.